Wall Street Looks To Pause After S&P's Record Performance As Fed Rate-Cut Euphoria Fades And Hard-Landing Fears Surface
The market mood appears to have soured as the index futures slid early Friday, which is expected to be volatile due to the triple witching phenomena. There could be a lack of incentive to buy for want of any major Main Street catalysts, as some economists have begun flashing the danger of a hard landing. Negative reaction to earnings released late Thursday may also serve as a dampener
Triple-witching refers to the simultaneous expiration of stock options, index options and index futures contracts, and the session is marked by increased volume and high volatility. This quarterly event will see some $5.1 trillion worth of options tied to individual stocks, indexes and exchange-traded funds fall off the board, Bloomberg reported, citing data analytics firm Asym 500.
Futures | Performance (+/-) |
Nasdaq 100 | -0.22% |
S&P 500 | -0.34% |
Dow | -0.03% |
R2K | -0.31% |
In premarket trading on Friday, the SPDR S&P 500 ETF Trust SPY fell 0.18% to $568.21 and the Invesco QQQ ETF QQQ slipped 0.31% to $481.86, according to Benzinga Pro data.
Cues From Last Session:
Pent-up buying perked up on Wall Street on Thursday, as risky bets rallied across the board, led by tech stocks, following the Fed’s first rate cut in about 4-1/2 years. Traders also drew comfort from a few positive economic data, including an unexpected drop in weekly jobless claims, the Philadelphia regional manufacturing activity unexpectedly turning to expansion territory and a smaller-than-expected drop in Conference Board’s leading economic index.
The S&P 500 Information Technology Index ended the day up 3.08%, while consumer discretionary and communication technology stocks also rose sharply. On the other hand, safe-haven consumer staples, utility and real-estate stocks pulled back modestly.
The major averages gap opened higher and moved roughly sideways before ending the session notably higher. The Nasdaq Composite Index ended at its highest level since July 16 and the S&P 500 Index ended at a fresh high and in the process scaled a new intraday high.
The 30-stock Dow Jones Industrial Average also hit new intraday and closing highs, as it went past the psychological resistance of 42,000 for the first time.
Making sense of Thursday’s market rally, Jamie Cox, Managing Partner at Harris Financial Group, said, “Markets like rate cuts, especially big ones when the economy is strong.”
Index | Performance (+/) | Value |
Nasdaq Composite | +2.51% | 18,013.98 |
S&P 500 Index | +1.70% | 5,713.64 |
Dow Industrials | +1.26% | 42,025.19 |
Russell 2000 | +2.10% | 2,252.71 |
Insights From Analysts:
Fund manager Louis Navellier said the economic risk is mitigated with the Fed rate cut and a new dot plot, which suggests more cuts could be in the offing this year. The housing sector also seems to be firming up, he said. Much of the economic uncertainty has been eliminated and so all investors have left to stress about is political uncertainty, he added.
Chief Global Strategist of BCA Research Peter Berezin said the 50 basis-point cut and another 50 bps reduction the central bank is penciling in before the year-end may not ensure a soft landing.
The economist noted that the Fed lowered rates by a cumulative 100 bps from Jan. to March 2001 and a recession started a month later, and the central bank implemented a cut of similar magnitude between Sept. 2007 – Dec. 2007 only for the Great Recession to begin in Jan. 2008.
Investors may be hoping for a repeat of the 1994-95 episode, when Fed easing paved the way for an economic boom, the economist said. There are at least three differences between then and now, he said. In 1994-95, the tightening was fairly mild, merely a cumulative 300 bps between Feb. 1994 and Feb. 1995, as opposed to the 525 bps increase this time around, he said. Also, unlike then, the unemployment rate is rising now, he added.
The second half of the 1990s saw a “massive disinflationary capex boom” coupled with rapid productivity growth but nothing comparable is evident in the data so far, Berezin said.
Upcoming Economic Data:
- Philadelphia Fed President Patrick Harker, who is a member of the rate-setting committee, is scheduled to speak at 2 p.m. EDT.
See Also: How To Trade Futures
Stocks In Focus:
- FedEx Corp. FDX shares fell over 13% in premarket trading following the company’s first-quarter earnings miss. Lennar Corporation LEN slipped over 2.5% after earnings.
- NIKE, Inc. NKE rose over 6.5% after the company announced John Donahoe will retire as CEO, effective Oct. 13, and Elliott Hill, a former Nike executive who retired in 2020, will return to take over from Donahoe.
Commodities, Bonds And Global Equity Markets:
Crude oil futures slipped after Thursday’s strong rally that took it past the $71-a-barrel level. Gold futures were in record territory despite the dollar coming back up. The 10-year U.S. Treasury note slid 2.5 points to 3.715%. Bitcoin BTC/USD has extended its rally, rising nearly 2% over the past 24 hours. The apex crypto, which topped $64K intraday, has eased off the day’s high and traded a little shy of the $63.5K mark.
Most major Asian markets advanced, with the exception of the Indonesian, New Zealand and Singaporean markets, while European stocks pulled back sharply in early trading after Thursday’s strong gains.
Read Next:
Image Via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
JIM WALTON Executes Sell Order: Offloads $170.98M In Walmart Stock
Revealing a significant insider sell on September 19, JIM WALTON, 10% Owner at Walmart WMT, as per the latest SEC filing.
What Happened: WALTON’s decision to sell 2,163,616 shares of Walmart was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The total value of the sale is $170,979,096.
Walmart‘s shares are actively trading at $78.96, experiencing a up of 1.18% during Friday’s morning session.
Unveiling the Story Behind Walmart
Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam’s Club) and over 10,000 stores globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam’s Club contributing another $86 billion to the company’s top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.
Walmart’s Financial Performance
Revenue Growth: Walmart’s revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately 4.77%. This indicates a substantial increase in the company’s top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Insights into Profitability:
-
Gross Margin: The company maintains a high gross margin of 25.11%, indicating strong cost management and profitability compared to its peers.
-
Earnings per Share (EPS): Walmart’s EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.56.
Debt Management: Walmart’s debt-to-equity ratio is below the industry average at 0.73, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics:
-
Price to Earnings (P/E) Ratio: Walmart’s current Price to Earnings (P/E) ratio of 40.65 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
-
Price to Sales (P/S) Ratio: The current P/S ratio of 0.95 is above industry norms, reflecting an elevated valuation for Walmart’s stock and potential overvaluation based on sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Walmart’s EV/EBITDA ratio, surpassing industry averages at 18.43, positions it with an above-average valuation in the market.
Market Capitalization: Positioned above industry average, the company’s market capitalization underscores its superiority in size, indicative of a strong market presence.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Importance of Insider Transactions
Insider transactions shouldn’t be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.
In the realm of legality, an “insider” is defined as any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
Unlocking the Meaning of Transaction Codes
Surveying the realm of stock transactions, investors often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Walmart’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
There's a 12% correction looming for the stock market by the end of the year, Stifel says
-
Stifel warns of a sharp stock market correction by year-end, with the S&P 500 potentially dropping 12%.
-
Chief equity strategist Barry Bannister said high valuations and speculative investor behavior are a concern.
-
“Our instruments tell us to expect an S&P 500 correction to the very low 5,000s by 4Q24,” Bannister said.
Investors should prepare for a sharp and quick correction in the stock market before the end of the year, according to Stifel.
In a note on Thursday, chief equity strategist Barry Bannister of Stifel warned that the S&P 500 could trade 12% lower in the fourth quarter.
“Our instruments tell us to expect an S&P 500 correction to the very low 5,000s by 4Q24,” Bannister said.
According to Bannister, there are a number of factors that are giving him cause for concern, including the idea that investors are exhibiting the type of behavior that is present during bubbles and manias.
“Just as countries that go rogue become almost un-investable, investors caught in the grips of a speculative fever become almost un-analyzable,” Bannister said.
For one, Bannister is concerned about current stock market valuations, which are approaching a “near three-generation high” based on the S&P 500’s price-to-earnings multiple of around 24x.
In addition, the sharp outperformance of large-cap growth stocks relative to value stocks is approaching the same peak seen in February 2000 and August 2020, which both served as a warning of an imminent bear market.
On the labor front, while Bannister admits that rising labor supply via increased immigration has supported economic growth, with US GDP growing at a rate above pre-pandemic trend levels, overall labor demand has been fading.
“Fading labor demand is now symbolic of recession risk,” Bannister said.
Bannister highlighted that the non-farm payroll 6-month diffusion index just crossed below a “recession trigger level.”
The diffusion index helps measure the breadth of job gains or losses across all economic industries.
Shifting to the election in November, Bannister said the typical “pre-election juice” for the economy is likely to fade towards the end of the year, as election promises from both sides of the aisle retreat and reality sets in that it’s hard to pass significant legislation in what could be a divided government.
“Pre-election juice for the economy may recede at year-end, causing stocks (which anticipate the future) to dip ~4 months in advance, and that is 4Q24E,” Bannister explained.
Finally, Bannister said that many investors are not appreciating the risks of a bubble in technology stocks, akin to what happened during the dot-com craze nearly 25 years ago.
“It takes one generation to forget the dangers of a bubble, and it is Groundhog Day versus the 1990s Tech Bubble; in reality ‘new tech’ isn’t even ‘new’ and today’s low Equity Risk Premium appears to us to lock-in a weak S&P 500 next-10-year compound annual real total return close to 3% real and 6% nominal,” Bannister said.
Read the original article on Business Insider
Maxeon Receives Nasdaq Notification and is Proceeding with Approved Reverse Stock Split
SINGAPORE, Sept. 20, 2024 /PRNewswire/ — Maxeon Solar Technologies, Ltd. MAXN (the “Company”), a global leader in solar innovation and channels, announced that on September 17, 2024, it received a Staff Determination letter (the “Determination Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities from The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) because, as of September 16, 2024, the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days.
On September 20, the Company submitted a hearing request through the Nasdaq Listing Center, which will automatically stay any delisting action or filing of the Form 25-NSE pending such hearing in accordance with Nasdaq Listing Rule 5815(a)(1).
On August 29, 2024, the shareholders of the Company at the Annual General Meeting of Shareholders approved by ordinary resolution the consolidation of every 100 existing issued ordinary shares (including treasury shares) into one ordinary share of the Company. The Company’s board of directors is in the process of taking the necessary actions to implement a reverse stock split which the Company believes will bring the bid price for the Company’s ordinary shares above the US$1.00 per share minimum bid price requirement as set forth by Nasdaq Listing Rule 5450(a)(1).
About Maxeon Solar Technologies
Maxeon Solar Technologies MAXN is Powering Positive Change™. Headquartered in Singapore, Maxeon leverages over 35 years of solar energy leadership and over 1,900 patents to design innovative and sustainably made solar panels and energy solutions for residential, commercial, and power plant customers. Maxeon’s integrated home energy management is a flexible ecosystem of products and services, built around the award-winning Maxeon® and SunPower® branded solar panels. With a network of more than 1,700 trusted partners and distributors, and more than one million customers worldwide, the Company is a global leader in solar. For more information about how Maxeon is Powering Positive Change™ visit us at www.maxeon.com, on LinkedIn and on Twitter/X @maxeonsolar.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including but not limited to, statements regarding the Company’s anticipated outcome of the litigation. The forward-looking statements can be also identified by terminology such as “may,” “might,” “could,” “will,” “aims,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements.
These forward-looking statements are based on our current assumptions, expectations and beliefs and involve substantial risks and uncertainties that may cause results, performance or achievement to materially differ from those expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to a number of risks. The reader should not place undue reliance on these forward-looking statements, as there can be no assurances that the plans, initiatives or expectations upon which they are based will occur. A detailed discussion of factors that could cause or contribute to such differences and other risks that affect our business is included in filings we make with the Commission from time to time, including our most recent report on Form 20-F, particularly under the heading “Risk Factors”. Copies of these filings are available online from the SEC at www.sec.gov, or on the SEC Filings section of our Investor Relations website at https://corp.maxeon.com/investor-relations. All forward-looking statements in this press release are based on information currently available to us, and we assume no obligation to update these forward-looking statements in light of new information or future events.
©2024 Maxeon Solar Technologies, Ltd. All Rights Reserved. MAXEON is a registered trademark of Maxeon Solar Technologies, Ltd. Visit https://corp.maxeon.com/trademarks for more information.
View original content to download multimedia:https://www.prnewswire.com/news-releases/maxeon-receives-nasdaq-notification-and-is-proceeding-with-approved-reverse-stock-split-302254415.html
SOURCE Maxeon Solar Technologies, Ltd.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
A Late-Friday Takeover Report Fires Up Intel's Stock
Key Takeaways
-
A late-Friday report that Qualcomm recently made a “takeover approach” to Intel sent the latter company’s shares higher.
-
Investors in Intel have read a raft of reports about possible M&A activity this week, with the company seemingly taking some options off the table.
-
Intel shares have lost more than half their value since the start of the year amid concerns about the chipmaker’s ability to turn around the business.
Shares of chipmaker Intel (INTC) popped in extended trading Friday, pulled higher by a report that Qualcomm (QCOM) had made a “takeover approach.”
The story in The Wall Street Journal, citing people familiar with the matter, said Qualcomm recently made a takeover approach to Intel. The news sent Intel’s stock up about 4%. Qualcomm’s was little changed, after falling close to 3% in the regular session.
Investors have in recent weeks considered a raft of stories about possible deal activity involving Intel, with Wall Street looking for signs that the company might be on a path to raising fresh capital or shoring up its businesses. The company this week, meanwhile, updated investors about its strategic plans and said a sale of its stake in Mobileye (MBLY) was off the table.
Qualcomm had been cited in some of those Intel reports. A takeover, however, would be particularly dramatic: Intel’s market capitalization was recently about $90 billion.
Intel’s shares are down more than 50% in 2024.
Read the original article on Investopedia.
Insider Decision: ROBSON WALTON Offloads $170.98M Worth Of Walmart Stock
It was reported on September 19, that ROBSON WALTON, 10% Owner at Walmart WMT executed a significant insider sell, according to an SEC filing.
What Happened: WALTON’s decision to sell 2,163,616 shares of Walmart was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The total value of the sale is $170,979,096.
Walmart shares are trading up 1.18% at $78.96 at the time of this writing on Friday morning.
Unveiling the Story Behind Walmart
Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam’s Club) and over 10,000 stores globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam’s Club contributing another $86 billion to the company’s top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.
Walmart: Financial Performance Dissected
Positive Revenue Trend: Examining Walmart’s financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.77% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Navigating Financial Profits:
-
Gross Margin: Achieving a high gross margin of 25.11%, the company performs well in terms of cost management and profitability within its sector.
-
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.56, Walmart showcases strong earnings per share.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.73.
Insights into Valuation Metrics:
-
Price to Earnings (P/E) Ratio: Walmart’s current Price to Earnings (P/E) ratio of 40.65 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
-
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 0.95 as compared to the industry average, the stock might be considered overvalued based on sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Walmart’s EV/EBITDA ratio stands at 18.43, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
Market Capitalization Analysis: With a profound presence, the company’s market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Delving Into the Significance of Insider Transactions
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
From a legal standpoint, the term “insider” pertains to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider’s new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
Navigating the World of Insider Transaction Codes
For investors, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Walmart’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Christian ONeil Exercises Options, Realizes $540K
A substantial insider activity was disclosed on September 19, as ONeil, President and COO at Kirby KEX, reported the exercise of a large sell of company stock options.
What Happened: ONeil, President and COO at Kirby, exercised stock options for 10,698 shares of KEX stock. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The exercise price of the options was $75.5 per share.
The Friday morning market activity shows Kirby shares down by 0.79%, trading at $126.02. This implies a total value of $540,462 for ONeil’s 10,698 shares.
Get to Know Kirby Better
Kirby Corp is a domestic tank barge operator, transporting bulk liquid products throughout three United States coasts. The Company transports petrochemicals, black oil, refined petroleum products, and agricultural chemicals by tank barge. The Company conducts operations in two reportable business segments: The Marine transportation segment which provides marine transportation services, operating tank barges and towing vessels transporting bulk liquid products, and the Distribution and services segment, which provides after-market service, and genuine replacement parts for engines, transmissions, reduction gears, and power generation equipment used in oil and gas and commercial and industrial applications. The company’s revenue is generated from the Marine Transportation segment.
A Deep Dive into Kirby’s Financials
Revenue Growth: Kirby displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.07%. This indicates a notable increase in the company’s top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Key Profitability Indicators:
-
Gross Margin: The company faces challenges with a low gross margin of 25.56%, suggesting potential difficulties in cost control and profitability compared to its peers.
-
Earnings per Share (EPS): Kirby’s EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 1.44.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.38.
Evaluating Valuation:
-
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 26.97 suggests caution, as the stock may be overvalued in the eyes of investors.
-
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 2.35 suggests overvaluation in the eyes of investors, considering sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Kirby’s EV/EBITDA ratio stands at 13.25, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
Market Capitalization: Surpassing industry standards, the company’s market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Unmasking the Significance of Insider Transactions
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Considering the legal perspective, an “insider” is defined as any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider’s new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
Deciphering Transaction Codes in Insider Filings
When analyzing transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Kirby’s Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don’t miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) — iBio, Inc. IBIO, an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.
“Our fiscal year 2024 was a transformational year for iBio, as we’ve solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics,” said CEO and Chief Scientific Officer Martin Brenner, Ph.D., DVM. “We made significant progress entering the fast-growing cardiometabolic and obesity space with our collaboration with AstralBio and strengthened our financial position by eliminating our debt associated with the facility and closing a fully subscribed financing including participation from Ikarian Capital, Lynx1 Capital Management, ADAR1 Capital Management, and other institutional and accredited investors. We continued to build our drug discovery platform, adding innovative technologies that are helping to advance our pipeline and provide critical support to our biopharma partners with best-in-class antibody discovery and development projects.”
Business Developments:
- Expanded the AI-powered technology stack with the launch of ShieldTx™, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue.
- In February, iBio closed the sale of its early-stage PD-1 asset to Otsuka Pharmaceutical Co., Ltd. for $1MM in upfront cash with contingent downstream payments of up to $52.5MM, a pivotal moment that showcased the power of iBio’s platform to discover best-in-class assets.
- Added bispecific capabilities with its EngageTx™ technology. We advanced a Trop2 x CD3 molecule to clinical candidate selection stage by demonstrating in a humanized mouse model of squamous cell carcinoma, a significant 36 percent reduction in tumor size 14 days after tumor implantation and after a single dose. Additionally, we leveraged our EngageTx technology and Epitope Steering technology to successfully develop multiple MUC16 x CD3 molecules, which show potent cell killing against ovarian cancer cells.
- Entered into a collaboration with AstralBio, Inc. to provide an exclusive license in the cardiometabolic and obesity space. iBio will develop four targets of interest with rights to license up to three of these targets prior to entering the clinic.
Corporate Developments:
- At the Company’s Special Meeting of Stockholders held on November 27, 2023, iBio’s stockholders authorized a reverse stock split, with a ratio ranging from 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board of Directors (the “Board”), and thereafter the Board approved a one for twenty (1-for-20) reverse stock split of the Company’s shares of common stock. The reverse stock split was effective November 29, 2023.
- Entered into a best-efforts public offering with investors in the fiscal second quarter for gross proceeds of approximately $4.5MM before deducting placement agent fees and offering expenses
- Entered into a securities purchase agreement for a private investment in public equity financing with several institutional investors and an accredited investor in the fiscal third quarter and consummated the financing in the fiscal fourth quarter for gross proceeds of approximately $15.0MM before deducting placement agent fees and offering expenses.
- During the third and fourth quarters, strengthened the Company’s cash position after previously issued warrants were exercised for proceeds of approximately $4.5MM.
- The Company closed the sale of its manufacturing facility located in Bryan, Texas (the “Property”) to the Board of Regents of the Texas A&M University System for $8.5MM. Following the issuance of pre-funded warrants having a value of $4.5MM to the lender, Woodforest National Bank, iBio and its wholly owned subsidiary, iBio CDMO LLC, satisfied all of the conditions of the settlement agreement releasing the Company and its subsidiary of all obligations with respect to the debt secured by the Property, which coupled with the release of approximately $915K in restricted cash previously held by Woodforest, eliminated approximately $13.2MM in secured debt from the Company’s balance sheet.
- Strengthened its Board of Directors and executive leadership team through the appointments of Dr. Brenner to the Board of Directors, effective June 1, 2024, and Kristi Sarno as Senior Vice President, Business Development, effective August 8, 2024.
“We ended this fiscal year well-positioned to advance our technology to drive value for patients and shareholders,” said Chief Financial Officer Felipe Duran. “We strengthened our balance sheet through capital raises and debt extinguishment. In fiscal year 2024, we executed transactions which brought in non-dilutive funding, and we continue to pursue business development projects to strengthen our financial position.”
Financial Results:
Revenues for the fiscal year ended June 30, 2024, were approximately $0.2 million, an increase of 100% over fiscal 2023.
R&D and G&A expenses for fiscal 2024 decreased $5.1 million and $7.3 million, respectively, over the comparable period in fiscal 2023. The decrease in R&D and G&A reflects the Company’s cost savings implemented to support its growing investments in its pipeline, platform technologies, employees, and related infrastructure.
iBio’s consolidated net loss for the fiscal year ended June 30, 2024, was $24.9 million, a decreased loss of $40.1 million compared to 2023 primarily because of the decrease in expenses related to the Company’s discontinued operations and cost saving initiatives.
iBio held cash, cash equivalents and restricted cash of $14.4 million as of June 30, 2024.
As disclosed in its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, which was filed on September 20, 2024 with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its registered public accounting firm that includes an explanatory paragraph related to the Company’s ability to continue as a going concern. See further discussion in footnote 2 to the Company’s financial statements included in the Company’s Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guide Sections 401(h) and 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph.
About iBio, Inc.
iBio is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers, and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements such as ending the fiscal year being well-positioned to advance the Company’s technology to drive value for patients and shareholders; and continuing to pursue business development projects to strengthen the Company’s financial position. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully advance its technology and continue to pursue business development projects to strengthen the Company’s financial position; its ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications; acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products; the continued maintenance and growth of its patent estate; its ability to establish and maintain collaborations and attract and increase partnership opportunities; competition; the substantial doubt exists related to the Company’s ability to operate as a going concern; its ability to raise additional capital in order to fully execute the Company’s longer-term business plans and the other factors discussed in the Company’s filings with the SEC including the Company’s Annual Report on Form 10-K for the year ended June 30, 2024. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Susan Thomas
iBio, Inc.
Media Relations
susan.thomas@ibioinc.com
iBio, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss
(In Thousands, except per share amounts)
Years Ended | ||||||||
June 30, | ||||||||
2024 | 2023 | |||||||
Revenues | $ | 225 | $ | — | ||||
Operating expenses: | ||||||||
Research and development | 5,185 | 10,327 | ||||||
General and administrative | 11,674 | 19,016 | ||||||
Total operating expenses | 16,859 | 29,343 | ||||||
Operating loss | (16,634 | ) | (29,343 | ) | ||||
Other income (expense): | ||||||||
Interest expense | (172 | ) | (83 | ) | ||||
Interest income | 363 | 213 | ||||||
Loss on sales of debt securities | — | (98 | ) | |||||
Gain on sale of intellectual property | 1,000 | — | ||||||
Total other income | 1,191 | 32 | ||||||
Net loss from continuing operations | (15,443 | ) | (29,311 | ) | ||||
Loss from discontinued operations | (9,464 | ) | (35,699 | ) | ||||
Net loss | $ | (24,907 | ) | $ | (65,010 | ) | ||
Comprehensive loss: | ||||||||
Consolidated net loss | $ | (24,907 | ) | $ | (65,010 | ) | ||
Other comprehensive loss – unrealized gain on debt securities | — | 180 | ||||||
Other comprehensive income – foreign currency adjustment | — | 33 | ||||||
Comprehensive loss | $ | (24,907 | ) | $ | (64,797 | ) | ||
Loss per common share attributable to iBio, Inc. stockholders – basic and diluted – continuing operations | $ | (4.03 | ) | $ | (47.88 | ) | ||
Loss per common share attributable to iBio, Inc. stockholders – basic and diluted – discontinued operations | $ | (2.47 | ) | $ | (58.31 | ) | ||
Loss per common share attributable to iBio, Inc. stockholders – basic and diluted – total | $ | (6.50 | ) | $ | (106.19 | ) | ||
Weighted-average common shares outstanding – basic and diluted | 3,831 | 612 | ||||||
iBio, Inc. and Subsidiaries
Consolidated Balance Sheets
(In Thousands, except share and per share amounts)
June 30, 2024 | June 30, 2023 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 14,210 | $ | 4,301 | ||||
Restricted cash | — | 3,025 | ||||||
Subscription receivable | — | 204 | ||||||
Promissory note receivable and accrued interest | 713 | — | ||||||
Prepaid expenses and other current assets | 749 | 664 | ||||||
Current assets held for sale (see Note 3 – Discontinued Operations) | — | 18,065 | ||||||
Total Current Assets | 15,672 | 26,259 | ||||||
Restricted cash | 215 | 253 | ||||||
Promissory note receivable | 1,081 | 1,706 | ||||||
Finance lease right-of-use assets, net of accumulated amortization | 339 | 610 | ||||||
Operating lease right-of-use asset | 2,401 | 2,722 | ||||||
Fixed assets, net of accumulated depreciation | 3,632 | 4,219 | ||||||
Intangible assets, net of accumulated amortization | 5,368 | 5,388 | ||||||
Security deposits | 26 | 50 | ||||||
Total Assets | $ | 28,734 | $ | 41,207 | ||||
Liabilities and Stockholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 358 | $ | 1,849 | ||||
Accrued expenses | 2,028 | 4,561 | ||||||
Finance lease obligations – current portion | 299 | 272 | ||||||
Operating lease obligation – current portion | 436 | 389 | ||||||
Equipment financing payable – current portion | 178 | 160 | ||||||
Term promissory note – current portion | 218 | — | ||||||
Insurance premium financing payable | 123 | — | ||||||
Term note payable – net of deferred financing costs | — | 12,937 | ||||||
Contract liabilities | 200 | — | ||||||
Current liabilities related to assets held for sale | — | 1,941 | ||||||
Total Current Liabilities | 3,840 | 22,109 | ||||||
Finance lease obligations – net of current portion | 53 | 351 | ||||||
Operating lease obligation – net of current portion | 2,688 | 3,125 | ||||||
Equipment financing payable – net of current portion | 63 | 241 | ||||||
Term promissory note – net of current portion | 766 | — | ||||||
Total Liabilities | 7,410 | 25,826 | ||||||
Stockholders’ Equity | ||||||||
Series 2022 Convertible Preferred Stock – $0.001 par value; 1,000,000 shares authorized at June 30, 2024 and June 30, 2023; 0 shares issued and outstanding as of June 30, 2024 and June 30, 2023 | — | — | ||||||
Common stock – $0.001 par value; 275,000,000 shares authorized at June 30, 2024 and June 30, 2023; 8,623,676 and 1,015,505 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively | 9 | 1 | ||||||
Additional paid-in capital | 335,162 | 304,320 | ||||||
Accumulated deficit | (313,847 | ) | (288,940 | ) | ||||
Total Stockholders’ Equity | 21,324 | 15,381 | ||||||
Total Equity | 21,324 | 15,381 | ||||||
Total Liabilities and Stockholders’ Equity | $ | 28,734 | $ | 41,207 |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Meet the Supercharged Growth Stock Headed to $10 Trillion by 2030, According to 1 Wall Street Analyst
There’s no denying that artificial intelligence (AI) has generated a lot of buzz since early last year. Recent technological advances have taken these algorithms to the next level, enabling them to generate original content of all stripes, improve productivity, and streamline processes.
Companies on the leading edge of this trend have profited from these advances in technology. In fact, six of the world’s seven most valuable companies, when measured by market cap, have embraced the paradigm shift of generative AI and staked their claims to profits from these next-generation systems. Topping the charts are Apple and Microsoft, the only two companies that currently boast a market cap of more than $3 trillion.
However, one company that appears ordained to make a name for itself as a founding member of the $10 trillion club is Nvidia (NASDAQ: NVDA). The pioneer in graphics processing units (GPUs) is nipping at the heels of the current leaders with a market cap of $2.8 trillion but seems destined to break new ground.
Let’s look at the numerous growth drivers that could send Nvidia stock to new heights.
Shall we play a game?
Nvidia revolutionized gaming a quarter of a century ago when the company pioneered the GPU, which produced lifelike images in video games. The secret to its success is parallel processing, or the ability of these advanced chips to process a multitude of mathematical calculations simultaneously. It wasn’t long before Nvidia realized the vast potential of this discovery and pivoted to tailor this technology to a host of other applications.
The company has since adapted GPUs to power cloud computing, data centers, machine learning, autonomous driving, generative AI, and more.
The tale of the tape
Over the past 10 years, Nvidia’s revenue has grown by 2,350% (as of this writing), while its net income has surged 9,490%. While it hasn’t all been in a straight line, the company’s consistently strong performance has driven impressive growth in its stock price, which has soared 23,110%.
In its fiscal 2025 second quarter (ended July 28), Nvidia delivered record revenue of $30 billion, up 122% year over year and 15% sequentially. This drove diluted earnings per share (EPS) of $0.67 up 168%. The star of the show was the data center segment, which includes processors used for cloud computing, data centers, and — of course — AI. Revenue for the segment surged 154% to $26.3 billion, driven by insatiable demand for AI.
There’s likely much more demand ahead. Analysts at Goldman Sachs Research estimate the economic impact of AI at $7 trillion by 2030. Furthermore, the improving macroeconomic backdrop could help accelerate adoption, which would be a boon to Nvidia.
Not a one-trick pony
There’s no question that AI is currently Nvidia’s biggest opportunity, but it’s far from the only one.
Let’s not forget that, until recently, GPUs for gaming were the company’s cash cow, while AI played second fiddle. During the economic downturn, many gamers made do with their existing processors, waiting for the specter of inflation to subside. As the economic outlook continues to improve and graphics cards come to the end of their useful lives, there’s plenty of pent-up demand that could fuel a long overdue upgrade cycle, and Nvidia stands to benefit the most.
In the first quarter, Nvidia controlled 88% of the discrete desktop GPU market, according to Jon Peddie Research. Furthermore, demand is expected to soar over the coming five years, jumping from $3.6 billion in 2024 to $15.7 billion by 2029, a compound annual growth rate (CAGR) of 34%, according to Mordor Intelligence. The market for gaming processors is ripe for a recovery, a trend that benefits Nvidia.
There’s also the data center market, which will be driven by the growing adoption of cloud computing. Many businesses are moving their data to the cloud, foregoing on-site storage, another trend that favors Nvidia. It controls an estimated 95% of the data center GPU market, according to Angelo Zino, senior equity analyst at CFRA Research.
It’s estimated that the data center market will climb from $302 billion in 2024 to $622 billion by 2030, a compound annual growth rate of 10%, according to data provided by Prescient and Strategic Intelligence Market Research.
Nvidia’s supremacy and the growing market puts the company in the pole position of another opportunity. Generative AI isn’t the only game in town. The company has a virtual monopoly in the machine learning market, an established branch of AI. The company controls an estimated 95% share of that market, according to New Street Research.
There are other areas that aren’t material to Nvidia’s growth but could eventually make a meaningful contribution. Self-driving cars aren’t yet ready for prime time, and quantum computing is still largely experimental, but either could be a catalyst for the next stage of Nvidia’s growth.
This helps illustrate the point that while generative AI is at the heart of Nvidia’s recent run-up, other opportunities abound.
The path to $10 trillion
Nvidia currently sports a market cap of roughly $2.78 trillion, which means it will take stock-price gains of 260% to drive its value to $10 trillion. According to Wall Street, Nvidia is poised to generate revenue of nearly $113 billion in fiscal 2025, giving it a forward price-to-sales ratio (P/S) of roughly 24.7. Assuming its P/S remains constant, Nvidia would need to grow its revenue to roughly $405 billion annually to support a $10 trillion market cap.
Wall Street is currently forecasting revenue growth for Nvidia of 47% annually over the next five years. If the company reaches that watermark, it could achieve a $10 trillion market cap as soon as 2029. But don’t take my word for it. Beth Kindig, CEO and lead tech analyst of the I/O Fund, has an estimate that’s eerily similar:
We believe Nvidia will reach a $10 trillion market cap by 2030 or sooner through a rapid product road map, it’s impenetrable moat from the CUDA software platform, and due to being an AI systems company that provides components well beyond GPUs, including networking and software platforms.
Given the company’s multiple avenues for growth and the accelerating adoption of AI, I think Kindig hit the nail on the head.
There’s a caveat, of course. Given Nvidia’s parabolic rise since early last year, any weakness by the company — real or perceived — could crush the stock price, at least temporarily. We’ve seen an example just recently when Nvidia lost nearly a quarter of its value over six weeks between June and July, as investors became skittish about rumors of a delay in the release of its next-generation Blackwell platform.
That said, I would submit that 36 times forward earnings is a reasonable price to pay for a company at the cutting edge of one of the biggest paradigm shifts in technology in a generation.
Should you invest $1,000 in Nvidia right now?
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $694,743!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of September 16, 2024
Danny Vena has positions in Apple, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Apple, Goldman Sachs Group, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Meet the Supercharged Growth Stock Headed to $10 Trillion by 2030, According to 1 Wall Street Analyst was originally published by The Motley Fool
Bitcoin, Ethereum, Dogecoin With A Meek Close To A Strong Week: 'Test Zones Coming Up For BTC,' Says Trader
Cryptocurrency markets are trading sideways, with Ethereum outperforming Bitcoin to end the week strong.
Cryptocurrency | Price | Gains +/- |
Bitcoin BTC/USD | $62,907.07 | -0.9% |
Ethereum ETH/USD | $2,544.07 | +3% |
Solana SOL/USD | $146.17 | +1.9% |
Dogecoin DOGE/USD | $0.1048 | -1.4% |
Shiba Inu SHIBA/USD | $0.00001414 | -1.1% |
Notable Statistics:
- IntoTheBlock data shows an increase of 10.5% in large transaction volume and a 4.8% surge in daily active addresses. Transactions greater than $100,000 increased from 8,206 to 9,567 in a single day. Exchanges netflows decreased by 147.2%.
- Coinglass data shows 62,203 traders liquidated in the past 24 hours for $149.39 million.
- Crypto chart analyst Ali Martinez stated that almost $2 billion in Bitcoin futures contracts were opened in just 48 hours. He added that this could be a potential long squeeze.
Notable Developments:
Top Gainers:
Cryptocurrency | Price | Gains +/- |
Sui SUI/USD | $1.49 | +11.6% |
Bittensor TAO/USD | $408.02 | +9.3% |
Aptos APT/USD | $7.26 | +6.4% |
Trader Notes: With Bitcoin prices dropping below $63,000, crypto trader Cold Blooded Shiller noted that test zones are coming up for Bitcoin. He said that the response is important whether the demand is bounced or swept.
Rekt Capital sees falling Bitcoin dominance (currently at 57.68%) entirely in line with the historical tendencies around these levels. He compared the situation to five years ago in mid-April 2019.
The trader posits that dominance is now dipping for a retest of this level into new support to confirm a breakout across the macro range.
Bitcoin is the same price range as it has been moving in since March, according to More Crypto Online, saying, “Should the price indeed move higher towards $67,000, then the trend line could offer additional resistance.”
Steve Courtney thinks Bitcoin’s RSI has broken out of its downtrend.
What’s Next: The influence of Bitcoin as an institutional asset class is expected to be thoroughly explored at Benzinga’s upcoming Future of Digital Assets event on Nov. 19.
Read Next:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.